Interviews

Stephanie Dwyer Kaluzna, PharmD, BCCP, discusses atrial fibrillation (AFib) anticoagulation risk stratification, therapy selection, and the emerging role of factor XI/XIa inhibitors.

Joseph Saseen, PharmD, discusses how pharmacists can overcome therapeutic inertia and sequence nonstatin therapies to help patients reach individualized LDL-C goals.

Advances in Alzheimer disease diagnosis and treatment are reshaping care, highlighting the pharmacist’s role in medication management, patient education, and overcoming barriers to access.

Cisgender Black and Brown women remain significantly underserved by PrEP due to provider knowledge gaps and medical mistrust.

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Jessica Dunne, PhD, discusses why adult T1D is frequently misdiagnosed as T2D and how autoantibody testing could close the diagnostic gap.

Josean Gonzalez, PharmD, BCPP, discusses the expanding role of pharmacists in Alzheimer disease care, Baptist Health South Florida’s multidisciplinary approach, and the promise of emerging therapies for patients with cognitive disorders.

Dave Dixon, PharmD, examines why SGLT2 inhibitor and GLP-1 uptake remain low and how pharmacists can bridge the gap between evidence and implementation.

Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.

Alyson Myers, MD, explains why expanded telehealth access, technology equity, and pharmacist partnerships are essential — not optional.

Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.

Erica Marini, PharmD, MS, BCPS; and guest Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments: a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on antiamyloid therapies.

Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.

Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.

GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.

Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.

SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.

APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.

Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.

Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.

Erin Zacholski, PharmD, BCOP, discusses the critical role of biomarker testing, immune checkpoint inhibitor selection, and pharmacist-led patient counseling in recurrent and metastatic endometrial cancer management.

Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.

Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.

Bundibugyo Ebola spreads in DRC and Uganda as the WHO declares a public health emergency of international concern; learn the case counts, travel alerts, and pharmacist readiness steps.

Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.

A board-certified psychiatric pharmacist breaks down how systemic fragmentation, access barriers, and policy gaps are undermining schizophrenia treatment—and what must change.

Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.